5-{2-methoxy-6-[2-(4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid methylamide | 885068-20-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-{2-methoxy-6-[2-(4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid methylamide
• 英文别名: 5-[2-methoxy-6-[2-(4-methoxyphenyl)ethylamino]pyrimidin-4-yl]-N-methylthiophene-2-carboxamide
• CAS: 885068-20-2
• 化学式: C₂₀H₂₂N₄O₃S
• 分子量: 398.486
• InChiKey: JAEOASXMHNSBPU-UHFFFAOYSA-N

物化性质

• 密度：
  1.262±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5-{2-methoxy-6-[2-(4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid methylamide 、 三氟乙酸 生成 5-{2-methoxy-6-[2-(4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid methylamide trifluoroacetate
  参考文献：
  名称：

  WO2008/39882

  摘要：

  公开号：
• 作为产物：
  描述：

  5-羧基噻吩-2-硼酸 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 caesium carbonate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 9.5h， 生成 5-{2-methoxy-6-[2-(4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid methylamide
  参考文献：
  名称：

  WO2008/39882

  摘要：

  公开号：

文献信息

• 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
  申请人：Lim Sungtaek

  公开号：US20070244131A1

  公开（公告）日：2007-10-18

  The present invention is directed to a compound of Formula (I) wherein Cy 1 , Cy 2 , L 1 , L 2 , and R 1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

  本发明涉及一种式（I）的化合物，其中Cy1，Cy2，L1，L2和R1如本文所定义，一种制药组合物，包括一种或多种按照式（I）的化合物的药物有效量与药学可接受载体的混合物，以及一种治疗患有PGD2介导的疾病的患者的方法，包括但不限于过敏性疾病（如过敏性鼻炎，过敏性结膜炎，特应性皮炎，支气管哮喘和食物过敏），全身性肥大细胞病，伴随全身性肥大细胞激活的疾病，过敏性休克，支气管收缩，支气管炎，荨麻疹，湿疹，伴随瘙痒的疾病（如特应性皮炎和荨麻疹），疾病（如白内障，视网膜脱落，炎症，感染和睡眠障碍），这些疾病是由于伴随瘙痒的行为（如搔抓和敲打）而次生产生的，炎症，慢性阻塞性肺疾病，缺血再灌注损伤，脑血管意外，慢性类风湿性关节炎，胸膜炎，溃疡性结肠炎等，通过向该患者注射按照式（I）的化合物的药物有效量。
• 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
  申请人：Aventis Pharmaceuticals Inc.

  公开号：EP1891019B1

  公开（公告）日：2012-07-25
• US7517889B2
  申请人：——

  公开号：US7517889B2

  公开（公告）日：2009-04-14
• US8193183B2
  申请人：——

  公开号：US8193183B2

  公开（公告）日：2012-06-05
• [EN] 2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS<br/>[FR] AMINO-PYRIDIMIDINE 2, 6-SUBSTITUEE-4-MONOSUBSTITUEE EN TANT QU'ANTAGONISTES DE RECEPTEUR DE LA PROSTAGLANDINE D2
  申请人：AVENTIS PHARMA INC

  公开号：WO2006044732A2

  公开（公告）日：2006-04-27

  [EN] The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).
  [FR] La présente invention a trait à un composé de formule (I) dans laquelle: Cy¹, Cy², L¹, L² et R1 sont tels que définis dans la description, à une composition pharmaceutique comprenant une quantité pharmaceutiquement efficace d'un ou de plusieurs composés de formule (I) en mélange avec un support pharmaceutiquement acceptable, et à un procédé de traitement d'un patient souffrant d'un trouble médié par la PGD2 comprenant, mais de manière non limitée, une maladie allergique (telle que la rhinite allergique, la conjonctivite allergique, la dermatite atopique, l'asthme et l'allergie alimentaire), la mastocytose systémique, des troubles accompagnés d'activation des mastocytes, le choc anaphylactique, la bronchoconstriction, la bronchite, l'urticaire, l'eczéma, les maladies accompagnées de démangeaison (telles que la dermatite atopique et l'urticaire), des maladies (telles que la cataracte, le décollement de la rétine, l'inflammation, l'infection et les troubles du sommeil) qui sont générées de manière secondaire conséquentes à un comportement accompagné de démangeaison (telles que griffures et battade), l'inflammation, les maladies obstructives respiratoires, la lésion ischémique au retour de la perfusion, l'accident vasculaire cérébral, la polyarthrite rhumatoïde chronique, la pleurésie, la colite ulcéreuse et analogues par l'administration au dit patient d'une quantité pharmaceutiquement efficace d'un composé de formule (I).